Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
28M
-
Number of holders
-
1
-
Total 13F shares, excl. options
-
21.8K
-
Shares change
-
-10.5M
-
Total reported value, excl. options
-
$128K
-
Value change
-
-$6.93M
-
Number of sells
-
-28
-
Price
-
$5.86
Significant Holders of NextCure, Inc. - Common Stock (NXTC) as of Q3 2025
28 filings reported holding NXTC - NextCure, Inc. - Common Stock as of Q3 2025.
NextCure, Inc. - Common Stock (NXTC) has 1 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 21.8K shares
of 28M outstanding shares and own 0.08% of the company stock.
Largest 10 shareholders include CARDIFF PARK ADVISORS, LLC (21.8K shares), GEODE CAPITAL MANAGEMENT, LLC (0 shares), HSBC HOLDINGS PLC (0 shares), VANGUARD GROUP INC (0 shares), BlackRock, Inc. (0 shares), Pfizer Inc (0 shares), JPMORGAN CHASE & CO (0 shares), ACADIAN ASSET MANAGEMENT LLC (0 shares), RENAISSANCE TECHNOLOGIES LLC (0 shares), and BARCLAYS PLC (0 shares).
This table shows the top 1 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.